# idiopathic pulmonary fibrosis (IPF) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 73004
- Completion tokens: 51935
- Reasoning tokens: 20406
- Total tokens: 124939
- API requests reported: 6
- Elapsed seconds: 174.941
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1387.824
- Question handoff seconds: 1401.194
- Final benchmark system: E2seq; file rank 3/5; original repeat 3; model vendor: MiniMax

---
<think>Let me analyze this complex IPF prognosis dataset carefully.

**Data Quality Assessment:**
The dataset has serious quality issues that I need to flag:
1. Several rows have HR values that are extreme/non-physical: HR ≈ 1.93e-22 (essentially zero, meaning infinitely protective) or HR ≈ 5.18e+21 (essentially infinite risk). These are computational artifacts.
2. P values of exactly 0 and FDR of exactly 0 are also computational artifacts.
3. CONTROL_A_33_P probes (CONTROL_A_33_P3222196, CONTROL_A_33_P3345409) are Affymetrix control probes - these shouldn't be in biological analysis at all.
4. Probes like MIR221, IHH, FAM75A2, OR2M2, DYDC2 with HR ~1.93e-22 are computational extremes likely from small subgroups or perfect separation.
5. Only LOC100128226 (HR=0.007) among the "protective" genes has a plausible HR value.
6. 93 of 100 genes are risk-associated (HR > 1), with plausible HRs ranging from ~2 to ~4.3.

**Real Data:**
The biologically meaningful risk-associated genes have HRs between 2.03 and 4.30, with FDRs ranging from 2.57e-06 to 3.99e-05. These represent genuine associations.

Let me identify key biological themes:

**Major Biological Programs:**

1. **Neutrophil/innate immune recruitment and activation** - CD177, CXCR1, CXCL1, CXCL14, CCL7, SELL, S100A12, S100A14, MERTK, STAB1, F5, MARCKS
   - GO: Neutrophil Migration (GO:1990266)
   - GO: Antimicrobial Humoral Immune Response Mediated By Antimicrobial Peptide (GO:0061844)
   - KEGG: Chemokine signaling pathway

2. **Epithelial injury/repair and mucociliary dysfunction** - MUC1, MUC21, TETs, SFTPB, SFTA2, SLC34A2, CEACAM6, CEACAM7, EMP2, MAL2, KRT17, KRT23, SPRR1A, EFEMP1
   - Alveolar epithelial type II cell dysfunction is a hallmark of IPF
   - Surfactant proteins, mucins, epithelial junction proteins

3. **Growth factor signaling and fibroblast activation** - HGF/MET, NRG1, BMP6, SPRY2, EFEMP1, HTRA1, FHL2, TGFB pathway components
   - HGF/MET signaling (STRING edge confirmed)
   - SPRY2 - negative feedback on MAPK/RTK signaling
   - BMP6 - TGF-β superfamily
   - HTRA1 - serine protease implicated in fibroblast activation

4. **Extracellular matrix remodeling and fibrosis** - MMP25, CHST15, HS3ST1, EFEMP1, SPP1, AGR3, FAM20A, BASP1, MARCKS, FBLIM1, PTP4A3, KANK1
   - SPP1 (Osteopontin) - well-known fibrosis marker
   - MMP25 - matrix metalloproteinase
   - CHST15 - chondroitin sulfation, implicated in fibroblast ECM

5. **Ion transport and metabolic reprogramming** - SLC34A2 (NaPi-IIb), SLC39A8 (ZIP8), SLC7A11 (xCT), SLC6A8 (creatine transporter), ACOX2, ALDH1A3, CYP4F3, STEAP4
   - Metabolic adaptation in fibrosis
   - SLC34A2 mutations cause pulmonary alveolar microlithiasis
   - SLC7A11 - cystine transport, ferroptosis defense

**Key Genes/Modules:**

1. **HGF/MET/NRG1** - receptor tyrosine kinase module
   - STRING edges: MET-HGF (0.999), MET-CBL (0.999), MET-EGFR (0.996)
   - SPRY2-CBL (STRING edge)
   - HGF/MET drives fibroblast migration in IPF

2. **Chemokine module** - CXCL1, CXCL14, CCL7, CXCR1
   - STRING cluster: CXCL5-CXCL1/CXCL14/CXCR1, CXCL6-CCL7/CXCL1/CXCR1
   - Neutrophil chemotaxis

3. **SPP1-FN1-HGF network** - CEACAM6, HGF, SPP1 connected via FN1
   - STRING: FN1 connects CEACAM6, HGF, SPP1
   - SPP1 is established IPF biomarker

4. **CD44/SELL/SLC7A11/SPP1** - STRING cluster via CD44
   - Cell adhesion/immune

5. **EFEMP1/SLC7A11/HGF/MET/MUC1/NRG1** - EGFR-centered module (STRING)

6. **MUC1/CEACAM6/MUC21** - epithelial/mucosal defense

7. **S100A12/S100A14** - danger-associated molecular patterns (DAMPs)

8. **HTRA1** - high-temperature requirement A1 serine protease, implicated in TGF-β activation and IPF

9. **CD177/SELL** - neutrophil adhesion

10. **SLC34A2** - alveolar type II cell phosphate transporter, mutations cause alveolar microlithiasis

**Validation Priorities:**

1. **HGF/MET/SPRY2 axis as therapeutic target hypothesis** - Druggable (MET inhibitors exist), but unclear if protective or pathogenic in IPF (MET inhibitors have actually been tried for IPF)
2. **SPP1 as prognostic biomarker** - Already established in IPF literature
3. **SLC7A11/ferroptosis axis** - Emerging area, SLC7A11 (xCT) protects against ferroptosis; fibroblast death in IPF is relevant
4. **Neutrophil score from CXCL1/CCL7/CXCR1/CD177/S100A12/SELL** - Biomarker
5. **Epithelial dysfunction signature (MUC1/SFTPB/SLC34A2/AGR3)** - Confounding/composition check
6. **Composition check via deconvolution** - the neutrophil and epithelial signatures could reflect cell composition shifts

**Limitations:**
1. Extreme HR values for several genes are likely computational artifacts (P=0, FDR=0, HR=1e-22 or 5e+21)
2. Control probes (CONTROL_A_33_P*) appearing as biological results - data quality issue
3. No independent cohort validation
4. IPF samples often have heterogeneous cellular composition (fibroblast foci, AEC2 hyperplasia, inflammation)
5. Cross-sectional lung tissue sampling cannot distinguish cause vs. consequence
6. Unknown covariates (age, sex, smoking, disease severity, treatment with antifibrotics)
7. Batch/platform effects

Let me write a comprehensive answer that addresses all these points. I need to:
1. Provide the data quality warning first
2. Then provide biological interpretation with the analysis components
3. Cite literature and external evidence where available
4. Not list all genes but focus on key programs and representatives

Let me structure this:

# IPF Prognosis - Multidimensional Interpretation

## Data Quality Warning
- Several rows have extreme/non-physical HR values
- Control probes present
- P=0/FDR=0 artifacts
- Cannot exclude computational artifacts vs. small subgroup effects

## 1. Overall biological interpretation
- Major biological themes...
- Prognostic risk dominated by activated fibroblast/myofibroblast, injured AEC2 epithelium, neutrophil/effector immune recruitment, and ECM remodeling signatures.

## 2. Core biological programs
- Program 1: Neutrophilic/effector immune infiltration and alarmin signaling
- Program 2: Alveolar epithelial injury and mucociliary dysfunction
- Program 3: Profibrotic growth factor signaling (HGF/MET/NRG1/BMP6/SPRY2)
- Program 4: Extracellular matrix remodeling and fibroblast activation
- Program 5: Solute carrier-mediated metabolic/ion dysregulation (SLC34A2, SLC7A11, SLC39A8, SLC6A8)

## 3. Key genes and interaction modules
- HGF/MET/SPRY2/NRG1/HGF axis
- CXCL1/CXCL14/CCL7/CXCR1 neutrophil chemotaxis
- SPP1/FN1/HGF/CEACAM6
- S100A12/S100A14 alarmin module
- SLC34A2/MUC1/SFTPB AEC2 injury
- SLC7A11/ferroptosis
- HTRA1
- CD177/SELL
- EFEMP1

## 4. Validation priorities
1. SPP1+neutrophil composite biomarker
2. HGF/MET axis - therapeutic targeting hypothesis
3. SLC7A11/ferroptosis in fibroblasts - mechanistic hypothesis
4. Epithelial deconvolution / cell-composition check
5. EFEMP1/HTRA1 as fibroblast activation markers

## 5. Evidence grounding
For each claim, list evidence categories

## 6. Limitations
- Data quality issues
- No replication cohort
- Composition effects
- Confounding by severity/treatment
- Cross-sectional sampling

Let me write this clearly and concisely.

I should be careful to:
- Cite literature only when the search returned relevant records (PMID 40487984 for KRT23 in MAFLD; PMID 28150878 for CYP4F3 in lung cancer GWAS; PMID 29217529 for FAM198B; PMID 31037515 for VGF in psychiatric disorders; PMID 35731246 for Ihh in osteoblasts; PMID 37471639 for SFTA2/CTS in lung cancer)
- Note that some literature is from non-IPF contexts
- Distinguish GO terms from evidence (the RAG batch listed GO:1990266 Neutrophil Migration, GO:1902744 Negative Regulation Of Lamellipodium Organization, GO:0061844 Antimicrobial Humoral Immune Response Mediated By Antimicrobial Peptide; KEGG: Chemokine signaling, viral protein-cytokine receptor, H. pylori epithelial signaling)

I should also mention STRING interaction networks:
- EGFR module: EFEMP1, HGF, MET, MUC1, NRG1
- CD44 module: SELL, SLC7A11, SPP1
- CXCL5 cluster: CXCL1, CXCL14, CXCR1
- CXCL6 cluster: CCL7, CXCL1, CXCR1
- FN1 cluster: CEACAM6, HGF, SPP1
- BASP1-MARCKS via CALML4/6
- MET-SPRY2 via CBL

Let me write the answer now. I'll keep it focused and clearly grounded.

Actually, I realize I should clarify what HR ~1.93e-22 means. A hazard ratio of 1.93e-22 essentially means no events in the high-expression group (or complete separation), which is mathematically extreme. The HR ~5.18e+21 means extreme over-risk. These should be flagged as artifacts. P=0 indicates the algorithm converged to perfect separation in some subgroup. The "protective" direction for these genes is also questionable because such extreme HRs typically indicate either a small subgroup with no events or a model convergence issue.

So for the "protective" genes:
- MIR221 (HR=1.93e-22) - computational artifact
- IHH (HR=1.93e-22) - computational artifact (Indian Hedgehog)
- FAM75A2 (HR=1.93e-22) - artifact, also possibly pseudogene
- OR2M2 (HR=1.93e-22) - artifact (olfactory receptor)
- XLOC_003303 (HR=1.93e-22) - artifact (lncRNA)
- DYDC2 (HR=1.93e-22) - artifact
- LOC100128226 (HR=0.007) - plausibly real

For the "risk" genes with extreme HR:
- CONTROL_A_33_P3222196, CONTROL_A_33_P3345409 - these are Affymetrix control probes, should not be in biological analysis
- HCN4 (HR=1.93e+21) - cardiac pacemaker channel, computationally extreme
- DKFZP434L187 (HR=5.18e+21) - artifact

I will explicitly note these issues. The 93 risk-associated genes with HR 2-4.3 are the substantive core of the analysis.

Now let me also make sure I capture the main point: this is a survival analysis, not differential expression. HR > 1 means higher expression is associated with higher mortality risk. The user has 93 risk genes and 7 protective genes (most with extreme HR artifacts).

Let me finalize the answer. I'll be concise but complete, following the structure requested.</think>

# Multidimensional interpretation of an IPF lung-tissue prognostic transcriptomic signature (all-cause mortality)

## 0. Data-quality warning (read first)

The supplied table contains **statistical artifacts that must be flagged before any biological inference**:

- **Non-physical hazard ratios.** Several rows report HR ≈ 1.93 × 10⁻²² (effectively zero) or HR ≈ 5.18 × 10²¹ (effectively infinite) with P = 0 and FDR = 0 (e.g., MIR221, IHH, FAM75A2, OR2M2, DYDC2, XLOC_003303; HCN4, DKFZP434L187, the two `CONTROL_A_33_P*` rows). These signatures are consistent with **perfect-separation / monotone-likelihood events in small subgroups** rather than with biology, and they dominate the "protective" count (5/7 protective genes carry such values).
- **Affymetrix control probes present as "genes."** `CONTROL_A_33_P3222196` and `CONTROL_A_33_P3345409` are poly-A / housekeeping control probes that should not have entered a biological selection. Their extreme HR values are not interpretable.
- **Only one plausible protective gene.** `LOC100128226` (HR ≈ 0.007, FDR ≈ 4.8 × 10⁻³⁵) is the lone entry with a finite, biologically plausible effect size; the other 6 "protective" labels cannot be trusted.
- **Consequence for interpretation.** The biological reading below is therefore built on the **93 risk-associated genes with finite HRs in the 2.0–4.3 range and FDR < 1 × 10⁻⁴**. The seven "protective" entries are not used to argue for protection.
- **No independent-cohort validation was performed in this analysis** (evidence-pack reports 0/0 concordant direction across an unspecified external cohort). The RAG-driven pathway, interaction and literature records below are *contextual*, not replicating.

With that caveat, the remaining signal is large, internally consistent and biologically coherent.

---

## 1. Overall biological interpretation

The 93 usable prognostic risk genes collectively describe a lung in which **injured alveolar epithelial type II (AEC2) cells, activated fibroblasts, and a neutrophil/effector immune infiltrate coexist with active extracellular matrix (ECM) remodeling and altered solute/metal handling**. Higher expression of this combined signature predicts earlier all-cause mortality in IPF. This is consistent with the prevailing model of IPF as a **bronchiolocentric / AEC2-driven fibrotic process with secondary innate-immune amplification** rather than a primary autoimmune disease: the molecular "footprint" is one of epithelial danger (S100 alarmin secretion, mucin/surfactant dysregulation, EGFR-family ligand/receptor activity), growth-factor-driven mesenchymal expansion (HGF/MET, NRG1, BMP6, SPRY2, HTRA1), neutrophil/effector recruitment (CXCL1/CCL7/CXCL14/CXCR1, CD177, SELL, S100A12/A14), and ECM/fibrosis effector activity (SPP1, MMP25, CHST15, EFEMP1, BASP1, MARCKS, FBLIM1). The strong representation of **SLC transporters (SLC34A2, SLC7A11, SLC39A8, SLC6A8, SLCO4A1)** and xenobiotic/lipid-metabolism genes (CYP4F3, ACOX2, ALDH1A3, STEAP4) suggests that **disturbed ion/metal homeostasis and a metabolic/oxidative-stress program** are also part of the lethal trajectory.

A second, more parsimonious reading is that some of these signals track **tissue composition** (more neutrophils, more fibroblasts, fewer intact AEC2s in end-stage IPF) rather than causal drivers; this is explicitly addressed in §6.

---

## 2. Core biological programs

### Program A — Neutrophil / effector-immune recruitment and alarmin signaling (prognostic risk)
- **Supporting genes:** CXCL1, CXCL14, CCL7, CXCR1, SELL, CD177, S100A12, S100A14, MERTK, STAB1, F5, MARCKS, VGF, PROK2, SSTR2.
- **Standardized terms:** GO:1990266 (neutrophil migration); GO:0061844 (antimicrobial humoral response mediated by antimicrobial peptide); KEGG *Chemokine signaling pathway*; Reactome *Neutrophil degranulation* (CD177 annotated to R-HSA-6798695).
- **Why these genes belong together:** CXCL1, CXCL14, CCL7 and CXCR1 are canonical neutrophil-attracting chemokines / receptors; CD177 and SELL are neutrophil-surface proteins that mediate adhesion and transendothelial migration; S100A12/A14 are neutrophil-derived alarmins (DAMPs) that amplify inflammation via TLR4/RAGE. MERTK and STAB1 are efferocytosis/scavenger receptors on macrophages that, in IPF, often reflect failed clearance of apoptotic neutrophils. The STRING network "CXCL5/CXCL6" hubs explicitly link CXCL1, CXCL14, CXCR1 and CCL7, confirming pathway co-membership rather than inferring physical binding.
- **Strength:** High internal coherence; pre-specified Reactome/GO annotation in the RAG pack (neutrophil degranulation, neutrophil migration). **Limitation:** No external cohort statistic was supplied; the program is well supported by the *signature* but not by *replication*.

### Program B — AEC2 / airway-epithelial injury, mucociliary dysfunction and EGFR-family stress (prognostic risk)
- **Supporting genes:** MUC1, MUC21, SFTPB, SFTA2, SLC34A2, CEACAM6, CEACAM7, EMP2, MAL2, PKP3, KRT17, KRT23, SPRR1A, AGR3, ALDH1A3, MET, NRG1.
- **Standardized terms:** KEGG *Epithelial cell signaling* (the H. pylori KEGG hit is a methodological placeholder, but the gene set maps more credibly to GO *epithelial cell differentiation/mucus secretion* and Reactome *Surfactant metabolism*); Hallmark *Epithelial mesenchymal transition* partially overlaps (KRT17, KRT23, S100A family).
- **Why these genes belong together:** MUC1/MUC21, CEACAM6/7, SFTPB, SFTA2 and SLC34A2 are **AEC2 / club-cell identity genes**, and their up-regulation in a poor-prognosis group is the canonical pattern of **reactive / dysplastic AEC2 (the "aberrant basaloid" cells recently described in IPF single-cell atlases)**. KRT17, KRT23 and SPRR1A are basaloid/stress-keratin markers that mark the same transitional epithelial state. MET and NRG1 are EGFR-family ligands/receptors that drive this regenerative-but-maladaptive response and connect to STRING's EGFR hub (EFEMP1, HGF, MET, MUC1, NRG1). SFTA2 has prior lung-cancer GWAS support (PMID 37471639), providing literature backing for a pulmonary-epithelial role.
- **Strength:** Strong coherence with established IPF single-cell biology (AEC2 stress / aberrant basaloid cells). **Limitation:** Whether the signature marks a *pathogenic* epithelial state or simply an *altered cell-type proportion* cannot be resolved from bulk HR data.

### Program C — Profibrotic growth-factor signaling and fibroblast activation (prognostic risk)
- **Supporting genes:** HGF, MET, NRG1, BMP6, SPRY2, HTRA1, FHL2, KANK1, EFEMP1, PTP4A3, STEAP4, SPP1.
- **Standardized terms:** KEGG *Cytokine–cytokine receptor interaction* (partial, via HGF/MET/NRG1); Reactome *MET receptor activation* (R-HSA-6806942), *RAF/MAPK cascade* (R-HSA-5673001), *PIP3 activates AKT* (R-HSA-1257604). STRING documents **direct physical interactions** MET–HGF (0.999), MET–CBL (0.999), MET–GRB2 (0.999), MET–EGFR (0.996), and MET–SPRY2 co-membership via CBL.
- **Why these genes belong together:** HGF and MET form the prototypical fibroblast-activating ligand/receptor pair; SPRY2 is an immediate-early feedback inhibitor of FGF/RTK/MAPK signaling that, when elevated, is a marker of *active* signaling rather than quiescence. NRG1/ERBB signaling is a documented fibroblast-activating pathway; BMP6 is a TGF-β-superfamily ligand that can be either pro- or anti-fibrotic depending on context. HTRA1 is a serine protease that **cleaves LTBP1 and activates latent TGF-β**, directly linking to fibroblast activation. FHL2, KANK1 and PTP4A3 are integrin/Rho-pathway adapters that drive fibroblast migration. SPP1 (osteopontin) is a well-established fibroblast and macrophage fibrotic effector and a known IPF prognostic biomarker in independent cohorts (literature-backed, not re-replicated here).
- **Strength:** Highest *protein-interaction*-supported program in the set; multiple STRING-documented direct physical interactions, not merely co-expression. **Limitation:** Direction of effect (HGF is conventionally *protective* in some IPF preclinical work, *risk* here) cannot be reconciled without external validation; HGF has even been tested as a therapy in IPF with mixed results.

### Program D — Extracellular matrix remodeling and fibroblastic foci (prognostic risk)
- **Supporting genes:** SPP1, MMP25, CHST15, HS3ST1, EFEMP1, FAM20A, BASP1, MARCKS, FBLIM1, PTP4A3, KANK1, AGR3, ENAH, F5, CD44-hub partners (SELL, SLC7A11, SPP1 via the STRING CD44 neighborhood), FN1-hub partners (CEACAM6, HGF, SPP1).
- **Standardized terms:** Reactome *Integrin signaling* / *ECM organization* (partial); KEGG *Focal adhesion*. STRING neighborhoods anchored on FN1, CD44, CALML4/CALML6 (BASP1, MARCKS) and the EGFR hub.
- **Why these genes belong together:** SPP1, CHST15 (chondroitin-4-sulfotransferase), HS3ST1 (heparan-sulfate 3-O-sulfotransferase), EFEMP1 (fibulin-3) and MMP25 are all direct modifiers of ECM composition. BASP1 and MARCKS are actin/membrane-skeleton organizers that mark a migratory, matrix-engaged mesenchymal state. The STRING *CD44 hub* (SELL, SLC7A11, SPP1) and *FN1 hub* (CEACAM6, HGF, SPP1) connect this program to Program A (neutrophils arrive on ECM) and Program C (fibroblast activation).
- **Strength:** Coherence of pathway co-membership is strong; STRING evidence here is co-expression / neighborhood rather than physical binding. **Limitation:** ECM signatures in bulk tissue may reflect fibroblast *abundance*, not activity per cell.

### Program E — Solute/metal homeostasis, metabolic reprogramming and ferroptosis defense (prognostic risk)
- **Supporting genes:** SLC34A2 (NaPi-IIb), SLC7A11 (xCT, cystine/GSH import), SLC39A8 (ZIP8, zinc/manganese), SLC6A8 (creatine transporter), SLCO4A1 (OATP, organic anion), ACOX2 (peroxisomal β-oxidation), ALDH1A3 (retinaldehyde dehydrogenase), STEAP4 (metalloreductase), CYP4F3 (leukotriene ω-hydroxylase).
- **Standardized terms:** GO *ion transport* / *transmembrane transport*; KEGG *Mineral absorption*, *Glutathione metabolism* (via SLC7A11); Reactome *SLC-mediated transmembrane transport*.
- **Why these genes belong together:** SLC34A2 is an **AEC2-specific phosphate transporter** (loss-of-function causes pulmonary alveolar microlithiasis) and a strong AEC2 identity marker; its elevated expression in poor-prognosis samples again suggests reactive AEC2s. **SLC7A11 is the rate-limiting cystine importer for the GSH/GPX4 axis that defends against ferroptosis**; this is mechanistically interesting because ferroptosis of fibroblasts has been proposed as a contributor to IPF progression and several groups have nominated SLC7A11 as a candidate regulator. CYP4F3 has prior GWAS support in lung (PMID 28150878), giving it independent disease-association evidence beyond this cohort. ALDH1A3, ACOX2 and STEAP4 point to retinoic-acid, peroxisomal-fatty-acid and metal-redox reprogramming — features increasingly reported in IPF fibroblasts.
- **Strength:** Mechanistically distinct and biologically novel axis (ferroptosis defense + ion dysregulation). **Limitation:** No independent replication; the SLC7A11/ferroptosis link to IPF mortality is an **exploratory** inference, not an established finding.

(These five programs were prioritized because they are mutually non-redundant — innate immune, epithelial, mesenchymal/growth-factor, ECM, and metabolic/ion — and each is supported by at least three independent selected genes and at least one external pathway/ontology or interaction record.)

---

## 3. Key genes and interaction modules (≤10)

| # | Candidate | Direction in dataset | Role in core programs | Relationship type (must be explicit) |
|---|---|---|---|---|
| 1 | **SPP1** (osteopontin) | Risk, HR ≈ 3.40, FDR ≈ 4.0 × 10⁻⁵ | D & C | STRING *co-expression/neighborhood* with CEACAM6, HGF via the FN1 hub; with SELL via the CD44 hub. Not a direct physical interaction. |
| 2 | **MET ↔ HGF** | Risk, HR ≈ 2.53 / 2.93, FDR ≈ 1.1–1.5 × 10⁻⁵ | C | **Direct physical interaction** (STRING 0.999). MET additionally binds CBL, GRB2, EGFR (STRING ≥0.996) — direct physical. |
| 3 | **SPRY2** | Risk, HR ≈ 3.26, FDR ≈ 1.7 × 10⁻⁵ | C | **Pathway co-membership** with MET via CBL (STRING); indicates active RTK/MAPK flux rather than quiescence. Not direct physical binding to MET itself. |
| 4 | **CXCL1 / CXCL14 / CCL7 / CXCR1** (chemokine module) | All risk, HR 2.4–3.3, FDR < 2 × 10⁻⁵ | A | **Co-expression/pathway co-membership** under STRING CXCL5/CXCL6 hubs; CXCL1/CXCL14 share the neutrophil chemotaxis program but the ligands do not physically bind each other — they act on the same receptor field. |
| 5 | **CD177 + SELL** | Risk, HR ≈ 2.72 / 2.37 | A | **Pathway co-membership** (neutrophil migration, leukocyte adhesion) and STRING *co-expression* via CD44 hub. CD177 has documented physical binding partners (PECAM1) per MyGene/QuickGO, but the CD177–SELL pair is co-membership, not physical binding. |
| 6 | **S100A12 + S100A14** | Risk, HR ≈ 2.53 / 2.57 | A | **Co-expression/pathway co-membership** as neutrophil/epithelial alarmins; literature supports *lactylation-associated* S100 biology in epithelial injury (Europe PMC 42074521). Physical heterodimerization within the S100 family is plausible but not demonstrated for this pair in the supplied evidence. |
| 7 | **HTRA1** | Risk, HR ≈ 4.30 (highest finite HR in set), FDR ≈ 2.6 × 10⁻⁶ | C | **Pathway co-membership** in TGF-β activation. HTRA1 is a *protease*, not a signaling receptor; its "interaction" with the HGF/MET/SPRY2 module is functional (ECM/TGF-β cleavage), not physical binding to those receptors. |
| 8 | **SLC7A11 (xCT)** | Risk, HR ≈ 3.52, FDR ≈ 1.1 × 10⁻⁵ | E & D | **Pathway co-membership** with SPP1/SELL via CD44 STRING hub. Mechanistically the rate-limiting cystine importer for the GSH/GPX4 ferroptosis-defense axis — proposed as a candidate regulator, not as an established IPF driver. |
| 9 | **EFEMP1 (fibulin-3)** | Risk, HR ≈ 2.33 | D & C | STRING *co-expression* with EGFR-hub neighbors (MET, HGF, MUC1, NRG1). ECM glycoprotein; a known circulating biomarker candidate in IPF/Age-related macular degeneration, but not yet an established IPF prognostic biomarker. |
| 10 | **MUC1 + SFTPB + SLC34A2** (AEC2 identity module) | Risk, HR 2.27–2.66 | B | **Co-expression/pathway co-membership** as AEC2 stress/injury markers. STRING does not document direct physical interactions among them; their joint behavior reflects a shared cell-state rather than a protein complex. |

Not used as "key" because of data-quality concerns: the seven "protective" genes (MIR221, IHH, FAM75A2, OR2M2, DYDC2, XLOC_003303, LOC100128226) — five of seven carry HR ≈ 10⁻²², a perfect-separation artifact; LOC100128226 (HR ≈ 0.007) is the only one with a usable effect size, and its gene identity is poorly annotated, so it is treated as exploratory.

---

## 4. Validation priorities

1. **Composite neutrophil / alarmin signature (CXCL1 + CCL7 + CXCR1 + CD177 + S100A12 + SELL) as a prognostic biomarker.**
   - *Class:* Biomarker.
   - *Why priority:* This module is the most externally annotated (Reactome neutrophil degranulation; KEGG chemokine signaling; GO neutrophil migration) and the most mechanistically tractable to score in blood or bronchoalveolar lavage, where IPF prognostic biomarkers are most actionable.
   - *Current-dataset evidence:* 6+ risk-associated genes, all HR ≥ 2.4, FDR ≤ 4 × 10⁻⁵.
   - *External support / conflict:* Pathway/ontology annotations are genuinely independent of the cohort (curated databases), but no independent-cohort statistic was computed here — so this is a *supported hypothesis*, not a validated biomarker.
   - *Next step:* Score the six-gene signature by qPCR / NanoString in an independent IPF whole-blood or BAL cohort with mortality follow-up, ideally against an existing antifibrotic-treated comparator arm.

2. **HGF/MET axis as a candidate therapeutic target in IPF.**
   - *Class:* Therapeutic target (also mechanistic).
   - *Why priority:* MET has direct physical interactors (HGF, CBL, GRB2, EGFR) in the cohort and there are clinically approved MET inhibitors (crizotinib, capmatinib, tepotinib). The *direction* of risk (higher HGF/MET expression → higher mortality) is consistent with these drugs being potentially harmful, but **the history of HGF/MET as a candidate IPF target is conflicted** (prior trials did not show clear benefit). Drug-target existence is **not** evidence of therapeutic efficacy.
   - *Current-dataset evidence:* HGF HR ≈ 2.93, MET HR ≈ 2.53, SPRY2 HR ≈ 3.26 (the SPRY2 elevation is informative: it implies active RTK flux).
   - *External support / conflict:* Reactome and STRING document a direct MET–HGF physical complex — strong mechanistic plausibility. *Conflict:* literature reports HGF as *protective* in some preclinical IPF models, which is at odds with the HR > 1 direction in this cohort.
   - *Next step:* Test whether MET expression stratifies response to antifibrotics (nintedanib/pirfenidone) in existing trial datasets; do **not** assume MET inhibition is therapeutic.
   - *Status:* Exploratory hypothesis.

3. **SLC7A11 / ferroptosis-defense axis in IPF fibroblasts (mechanistic hypothesis).**
   - *Class:* Mechanistic hypothesis.
   - *Why priority:* SLC7A11 (HR ≈ 3.52) is the rate-limiting cystine importer for the GSH/GPX4 ferroptosis-defense system; ferroptosis has emerged as a candidate mechanism of fibroblast death and pathologic epithelial remodeling in IPF. This is biologically novel, experimentally testable, and connects to drug-target space (erastin/sulfasalazine as inducers, ferrostatin-1 as inhibitor).
   - *Current-dataset evidence:* Single gene with strong risk HR; co-membership with the CD44 STRING hub; not enough genes in the cohort to claim a "program."
   - *External support:* Reactome/UniProt/SLC transporter pathway annotations; no IPF-specific replication here.
   - *Next step:* Quantify SLC7A11 and PTGS2 (ferroptosis marker) in IPF vs. control fibroblasts by IHC; perform erastin sensitivity assays on patient-derived fibroblasts stratified by SLC7A11 expression.
   - *Status:* Exploratory hypothesis.

4. **AEC2-stress / aberrant-basaloid signature (MUC1 + SFTPB + SLC34A2 + KRT17 + KRT23 + SPRR1A) as a *cell-composition check* rather than a causal pathway.**
   - *Class:* Confounding or composition check.
   - *Why priority:* The single most important alternative explanation for the observed mortality association is that end-stage IPF lungs simply have **more reactive AEC2 / basaloid cells and fewer quiescent AEC1 cells**, biasing bulk transcriptomic HRs toward cell-type frequency rather than causal biology. The same caution applies to the neutrophil and fibroblast modules.
   - *Current-dataset evidence:* Six AEC2 / basaloid markers all HR > 1, FDR < 4 × 10⁻⁵ — a strong but ambiguous signal.
   - *External support:* KRT23 has external literature (PMID 40487984, though in MAFLD not IPF) — useful as evidence the gene is biologically active, not as IPF replication. SFTA2 has lung-cancer GWAS support (PMID 37471639).
   - *Next step:* Re-run Cox models with cell-type proportions (deconvolution against published IPF single-cell references, e.g. Adams/Sheppard/Kaminski atlases) and report whether each module's HR is attenuated after adjustment.
   - *Status:* Supported hypothesis (that composition matters) → currently *unmeasured*.

5. **EFEMP1 (fibulin-3) and HTRA1 as candidate prognostic biomarkers and fibroblast-activation markers.**
   - *Class:* Biomarker + mechanistic hypothesis.
   - *Why priority:* EFEMP1 (HR ≈ 2.33) is a circulating ECM glycoprotein with prior biomarker literature; HTRA1 (HR ≈ 4.30, the strongest finite HR in the cohort) is mechanistically attractive because it cleaves LTBP1 and activates TGF-β — a direct fibrosis-relevant protease.
   - *Current-dataset evidence:* Two genes with strong HR and plausible biology.
   - *External support:* STRING co-expression with the EGFR hub (EFEMP1); QuickGO and UniProt annotations of HTRA1 as a serine protease — both contextual, not IPF-specific replication.
   - *Next step:* Measure plasma fibulin-3 and HTRA1 in an independent IPF cohort with mortality data; correlate with TLC/DLCO decline.
   - *Status:* Supported hypothesis.

---

## 5. Evidence grounding (claim → evidence class → independence)

| Claim | Direct dataset evidence | Pathway/ontology | Interaction network | Tissue/expression | Disease/GWAS | Drug/therapeutic | Literature |
|---|---|---|---|---|---|---|---|
| Neutrophil recruitment module (Program A) | Yes (HR/P/FDR on CXCL1, CXCL14, CCL7, CXCR1, CD177, SELL) | Yes — GO:1990266, KEGG chemokine signaling | Yes — STRING CXCL5/CXCL6 hubs | Yes — CD177 in HPA/GTEx as neutrophil-restricted | Partial — no IPF-specific GWAS in pack | No | No IPF-specific lit in pack |
| AEC2 stress module (Program B) | Yes (HR on MUC1, SFTPB, SLC34A2, KRT17/23, SPRR1A) | Yes — surfactant, keratinization terms | STRING EGFR hub | Yes — SLC34A2 is AEC2-restricted (HPA/UniProt) | Partial — SFTA2 lung-cancer GWAS (PMID 37471639) | No | PMID 37471639 (SFTA2), 40487984 (KRT23) |
| Profibrotic signaling (Program C) | Yes (HGF, MET, NRG1, BMP6, SPRY2, HTRA1) | Reactome MET activation, RAF/MAPK | Yes — **direct physical**: MET–HGF (0.999), MET–CBL, MET–EGFR | Partial — HPA MET/HGF expression | No IPF-specific | MET inhibitors exist (crizotinib/capmatinib/tepotinib) | SPP1 has IPF literature; HGF/MET mixed |
| ECM / fibroblastic foci (Program D) | Yes (SPP1, MMP25, CHST15, EFEMP1, BASP1, MARCKS) | Partial — integrin/ECM terms | STRING CD44, FN1, CALML4/6 hubs | Yes | No | No | SPP1 IPF lit external |
| SLC / ferroptosis (Program E) | Yes (SLC7A11, SLC34A2, SLC39A8, SLC6A8) | Yes — SLC-mediated transport, GSH metabolism | STRING CD44 hub (SLC7A11) | Yes | CYP4F3 lung-cancer GWAS (PMID 28150878) | SLC7A11 has drug-target space (erastin/sulfasalazine) | Europe PMC 42074521 on S100 family (non-IPF) |

**Independence caveat.** The pathway/ontology, network, tissue-expression, and disease-association columns largely derive from **curated databases (Reactome, QuickGO, STRING, HPA, UniProt, GTEx, GWAS catalog)** that share underlying gene-annotation provenance. They should be regarded as **one partially independent layer** of context, not as five independent replications. Genuinely independent evidence comes only from (i) the uploaded cohort statistics, (ii) an external IPF cohort (not supplied), and (iii) PubMed/Europe PMC primary publications (which themselves often rely on overlapping GEO datasets). The IPF-relevant literature in the pack is sparse; the retrieved records (PMID 40487984, 28150878, 29217529, 31037515, 35731246, 37471639; Europe PMC 42074521) address KRT23 in MAFLD, CYP4F3 in lung cancer, FAM198B in lung adenocarcinoma, VGF in psychiatric disease, Ihh in skeletal dysplasia and SFTA2/CTS in lung cancer — useful as gene-function context but **not** as IPF-specific replication. No conflict between sources was identified for the directional claims, but absence of conflict is not equivalent to confirmation.

---

## 6. Limitations and alternative explanations

1. **Computational artifacts dominate the "protective" group.** 5 of 7 protective entries have HR ≈ 10⁻²² and P = 0, the signatures of perfect separation in small or empty subgroups. **Investigation:** Repeat the Cox fits with penalized/Firth regression and report penalized HRs; remove strata with < N events; cross-check against KM curves and event counts.

2. **Affymetrix control probes are misclassified as biological hits** (`CONTROL_A_33_P3222196`, `CONTROL_A_33_P3345409`). These should never appear in a prognostic signature; they should be masked upstream. **Investigation:** Re-run from raw CEL files with proper probe filtering, and verify probe-to-gene mappings (the `CONTROL_A_*` and `BX117289`/`AK309441`/`AK096792`/`lincRNA:*` records imply a non-standard annotation pipeline).

3. **Cell-composition confounding.** The neutrophil, AEC2-stress and fibroblast modules are each consistent with **shifts in cellular composition** in end-stage IPF (more neutrophils and reactive AEC2/basaloid cells, more fibroblasts). Without single-cell deconvolution or cell-type-specific HRs, "expression predicts mortality" cannot be distinguished from "cell frequency predicts mortality." **Investigation:** Deconvolve bulk profiles against an IPF single-cell reference atlas and adjust Cox models for the inferred cell-type fractions; ideally validate by IHC or spatial transcriptomics.

4. **Confounding by clinical covariates.** Standard IPF prognostic factors (age, sex, baseline FVC% / DLCO%, GAP index, antifibrotic treatment exposure, smoking status, disease duration, acute exacerbation history) are not part of the supplied model. **Investigation:** Report multivariable Cox HRs adjusted for GAP stage and antifibrotic use.

5. **Association ≠ causation and cross-sectional sampling.** Lung-tissue transcriptomics at one time point cannot distinguish a causal driver of fibrosis progression from an injury response that simply tracks disease severity. The cohort is "lung tissue" without specification of sampling site (fibroblast foci vs. histologically spared), so spatial heterogeneity within the lung is also a concern. **Investigation:** Sample-matched bulk + spatial transcriptomics; longitudinal sampling; functional perturbation (e.g., CRISPR or siRNA knockdown of SLC7A11 or SPRY2 in patient-derived fibroblasts).

A final cross-cutting limitation is that **no independent cohort was actually replicated here**: the evidence-pack records "direction concordant 0/0" for external validation. All "supported" findings above are *internally* supported only; claims of external validation, clinical utility, or therapeutic efficacy should be treated as **exploratory hypotheses** until an independent IPF survival cohort is analyzed with the same gene set.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=12, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 77/100 selected items (partially returned; some queries failed); cbioportal 78/100 selected items (records returned); chembl 13/100 selected items (partially returned; some queries failed); civic 8/100 selected items (records returned); clinicaltrials 48/100 selected items (records returned); clinvar 78/100 selected items (records returned); ensembl 25/100 selected items (partially returned; some queries failed); europepmc 860 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 78/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 81/100 selected items (partially returned; some queries failed); mygene 91/100 selected items (records returned); omnipath 47/100 selected items (records returned); opentargets 80/100 selected items (partially returned; some queries failed); pubmed 658 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 83/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 84/100 selected items (records returned)
Local databases: gutmgene 3/100 selected items (records returned); hmdb 32/100 selected items (records returned); string 79/100 selected items (records returned); trrust 25/100 selected items (records returned)
